SEARCH

SEARCH BY CITATION

References

  • Ameri A. (1999) The effects of cannabinoids on the brain. Prog. Neurobiol. 58, 315348.
  • Antunes F., Cadenas E. and Brunk U. T. (2001) Apoptosis induced by exposure to a low steady-state concentration of H2O2 is a consequence of lysosomal rupture. Biochem. J. 356, 549555.
  • Blázquez C., Sánchez C., Daza A., Galve-Roperh I. and Guzmán M. (2003) The stimulation of ketogenesis by cannabinoids in cultured astrocytes defines carnitine palmitoyltransferase 1 as a new ceramide-activated enzyme. J. Neurochem. 72, 17591768.
  • Blomgren K., Leist M. and Groc L. (2007) Pathological apoptosis in the developing brain. Apoptosis 12, 9931010.
  • Britton R. S. and Mellors A. (1973) Lysis of rat liver lysosomes in vitro by tetrahydrocannabinol. Biochem. Pharmacol. 23, 13421344.
  • Brunk U. T., Neuzil J. and Eaton J. W. (2001) Lysosomal involvement in apoptosis. Redox Rep. 6, 9197.
  • Campbell V. A. (2001) Tetrahydrocannabinol-induced apoptosis in cultured cortical neurones is associated with cytochrome c release and caspase-3 activation. Neuropharmacology 40, 702709.
  • Campbell V. and Gowran A. (2007) Alzheimer’s disease’ taking the edge off with cannabinoids? Br. J. Pharmacol. 152, 655662.
  • Carlson G., Wang Y. and Alger B. E. (2002) Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat. Neurosci. 5, 723724.
  • Carracedo A., Gironella M., Lorente M., Garcia S., Guzman M., Velasco G. and Iovanna J. L. (2006) Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 66, 67486755.
  • Chan G. C., Hinds T. R., Impey S. and Storm D. (1998) Hippocampal neurotoxicity of Δ9-tetrahydrocannabinol. J. Neurosci., 18, 53225332.
  • Chen C. S., Chen W. N., Zhou M., Arttamangkul S. and Haugland R. P. (2000) Probing the cathepsin using a BODIPY FL-pepstatin A: applications in florescence p olarization and microscopy. J. Biochem. Biophys. Methods 42, 137151.
  • Chipuk J. E., Kuwana T., Bouchier-Hayes L., Droin N. M., Newmeyer D. D., Schuler M. and Green D. R. (2005) Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 13, 10101014.
  • Chua C. C., Liu X., Gao J., Hamdy R. C. and Chua B. H. L. (2006) Multiple actions of pifithrin-α on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells. Am. J. Physiol. 290, H2606H2613.
  • Culmsee C., Zhu X., Yu Q. S., Chan S. L., Camandola S., Guo Z., Greig N. H. and Mattson M. (2001) A synthetic inhibitor of p53 protects neurones against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J. Neurochem. 77, 220228.
  • Derkinderen P., Valjent E., Toutant M., Corvol J.-C., Enslen H., Ledent C., Trzaskos J., Caboche J., and Girault J.-A. (2003) Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J. Neurosci. 23, 23712382.
  • Downer E., Boland B., Fogarty M. P., Campbell V. and (2001) Δ9-Tetrahydrocannabinol induces the apoptotic pathway in cultured cortical neurones via activation of the CB1 receptor. Neuroreport 12, 39733978.
  • Downer E. J., Fogarty M. P. and Campbell V. A. (2003) Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurones. Br. J. Pharm. 140, 547557.
  • Downer E. J., Gowran A. and Campbell V. A. (2007a) A comparison of the apoptotic effect of Δ9-tetrahydrocannabinol in the neonatal and adult rat cerebral cortex. Brain Res. 1175, 3947.
  • Downer E. J., Gowran A., Murphy A. C. and Campbell V. A. (2007b) The tumour suppressor protein, p53, is involved in the activation of the apoptotic cascade by Delta9-tetrahydrocannabinol in cultured cortical neurones. Eur. J. Pharmacol. 564, 5765.
  • Fride E. (2005) Endocannabinoids in the central nervous system, from neuronal networks to behavior. Curr. Drug Targets CNS Neurol. Disord. 4, 633642.
  • Fried P. A. and Smith A. M. (2001) A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol. Teratol. 23, 111.
  • Galve-Roperh I., Sánchez C., Luisa Cortes M., Gómez del Pulgar T., Izquierdo M. and Guzmán M. (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6, 313319.
  • Galve-Roperh I., Aquado T., Rueda D., Velasco G. and Guzman M. (2006) Endocannabinoids: a new family of lipid mediators involved in the regulation of neural cell development. Curr. Pharm. Des. 12, 23192325.
  • Gilbert G. L., Kim H. J., Waataja J. J. and Thayer S. A. (2007) Delta9-tetrahydrocannabinol protects hippocampal neurones from excitotoxicity. Brain Res. 1128, 6169.
  • Green D. R. and Chipuk J. E. (2006) p53 and metabolism: inside the TIGAR. Cell 126, 3032.
  • Guzman M. (2005) Effects on cell viability. Handb. Exp. Pharmacol. 168, 627642.
  • Hampson A. J., Grimaldi M., Axelrod J. and Wink D. (1998) Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl Acad. Sci. USA 95, 82688273.
  • Harkany T., Guzmán M., Galve-Roperh I., Berghuis P., Devi L. A. and Mackie K. (2007) The emerging functions of endocdannabinoid signalling during CNS development. Trends Pharmacol. Sci. 28, 8392.
  • He J., Tohyama Y., Yamamoto K., Kobavashi M., Shi Y., Takano T., Noda C., Tohyama K. and Yamamura H. (2005) Lysosome is a primary organelle in B cell receptor-mediated apoptosis: an indispensable role of Syk in lysosomal function. Genes Cells 10, 2335.
  • Herkenham M., Lynn A. B., Johnson M. R., Melvin L. S., De Costa B. R. and Rice K. C. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563583.
  • Houseweart M. K., Vilaythong A., Yin X. M., Turk B., Noebels J. L. and Myers R. M. (2003) Apoptosis caused by cathepsins does not involve Bid signaling in an in vivo model of progressive myoclonus epilepsy (EPM1). Cell Death Differ. 10, 13291335.
  • Jia W., Hegde V. L., Singh N. P., Sisco D., Grant S., Nagarkatti M. and Nagarkatti P. S. (2006) Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol. Cancer Res. 4, 549562.
  • Johansson A. C., Steen H., Ollinger K. and Roberg K. (2003) Cathepsin D mediates cytochrome c releaser and caspase activation in human fibroblast apoptosis induced by starausporine. Cell Death Differ. 10, 12531259.
  • Kaasik A., Rikk T., Piirsoo A., Zharkovsky T. and Zharkovsky A. (2005) Up-regulation of lysosomal cathepsin-L and autophagy during neuronal death induced by reduced serum and potassium. Eur. J. Neurosci. 22, 10231031.
  • Kagedal K., Johansson A. C., Johansson U., Heimlich G., Roberg K., Wang N. S., Jurgensmeier J. M. and Ollinger K. (2005) Lysosomal membrane permeabilization during apoptosis: involvement of Bax? Int. J. Exp. Pathol. 86, 309321.
  • Kågedal K., Zhao M., Svensson I. and Brunk U. T. (2001) Sphingosine-induced apoptosis is dependent on lysosomal proteases. Biochem. J. 359, 335343.
  • Kalra J., Chaudhary A. K. and Prasad K. (1989) Role of oxygen free radicals and pH on the release of cardiac lysosomal enzymes. Mol. Cell Cardiol. 21, 11251136.
  • Kishimoto Y. and Kano M. (2006) Endogenous cannabinoid signalling through the CB1 receptor is essential for cerebellum-dependent discrete motor learning. J. Neurosci. 26, 88298837.
  • Komarov P. G., Komarova E. A., Kondratov R. V., Christov-Tselkov K., Coon J. S., Chernov M. V. and Gudkov A. V. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer. Science 285, 17331737.
  • Lawston J., Borella A., Robinson J. K. and Whitaker-Azmitia P. M. (2000) Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55212-2. Brain Res. 877, 407410.
  • Li W., Yuan X., Nordgren G., Dalen H., Dubowchik G. M., Firestone R. A. and Brunk U. T. (2000) Induction of cell death by the lysosomotropic detergent MSDH. FEBS Lett. 470, 3539.
  • Ligresti A., Moriello A. S., Starowicz K., Matias I., Pisanti S., De Petrocellis L., Laezza C., Portella G., Bifulco M. and Di Marzo V. (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther. 318, 13751387.
  • Lyman W. D., Sonett J. R., Brosnan C. F., Elkin R. and Bornstein M. B. (1989) Δ9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 23, 7381.
  • MacManus A., Ramsden M., Murray M., Pearson H. A. and Campbell V. (2000) Enhancement of 45Ca2+ influx and voltage-dependent Ca2+ channel activity by β-amyloid(1–40) in rat cortical synaptosomes and cultured cortical neurones: modulation by the proinflammatory cytokine interleukin-1β. J. Biol. Chem. 275, 47134718.
  • Massi P., Vaccani A., Bianchessi S., Costa B., Mcchi P. and Parolaro D. (2006) The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol. Life Sci. 63, 20572066.
  • Mathiasen I. S. and Jäättelä M. (2002) Triggering caspase-independent cell death to combat cancer. Trends Mol. Med. 5, 212220.
  • Matochik J. A., Eldreth D. A., Cadet J. L. and Bolla K. I. (2005) Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend. 77, 2330.
  • Matveyeva M., Hartmann C. B., Harrison M. T., Cabral G. A. and McCoy K. L. (2000) Delta (9)-tetrahydrocannabinol selectively increases aspartyl cathepsin D proteolytic activity and impairs lysozyme processing by macrophages. Int. J. Immunopharmacol. 22, 373381.
  • Moore T. H., Zammit S., Lingford-Hughes A., Barnes T. R., Jones P. B., Burke M. and Lewis G. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319328.
  • Movsesyan V. A., Stoica B. A., Yakoviev A. G., Knoblach S. M., Lea P. M., Cernak I., Vink R. and Faden A. I. (2004) Anandamide-induced cell death in primary neuronal cultures: role of calpain and caspase pathways. Cell Death Differ. 11, 11211132.
  • Ollinger K. and Brunk U. T. (1995) Cellular injury induced by oxidative stress is mediated through lysosomal damage. Free Radic. Biol. Med. 19, 565574.
  • Raman C., McAllister S. D., Rizvi G., Patel S. G., Moore D. H. and Abood M. E. (2004) Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 5, 3339.
  • Ranganathan M. and De Souza D. C. (2006) The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology 188, 425444.
  • Reiners J. J. Jr, Caruso J. A., Mathieu P., Chelladurai B., Yin X. M. and Kessel D. (2002) Release of cytochrome c and activation of pro-caspase-9 following lysosomal photodamage involves Bid cleavage. Cell Death Differ. 9, 934944.
  • Roberg K. and Ollinger K. (1998) Oxidative stress causes relocation of the lysosomal enzyme cathepsin D with ensuing apoptosis in neonatal rat cardiomyocytes. Am. J. Pathol. 152, 11511156.
  • Sarafian T., Habib N., Mao J. T., Tsu I. H., Yamamoto M. L., Hsu E., Tashkin D. P. and Roth M. D. (2005) Gene expression changes in human small airway epithelial cells exposed to Δ9-tetrahydrocannabinol. Toxicol. Lett. 158, 95107.
  • Scallet A. C. (1991) Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol. Biochem. Behav. 40, 671676.
  • Schestkowa O., Geisel D., Jacob R. and Hasilik A. (2007) The catalytically inactive precursor of cathepsin D induces apoptosis in human fibroblasts and HeLa cells. J. Cell. Biochem. 101, 15581566.
  • Schlaepfer T. E., Lancaster E., Heidbreder R., Strain E. C., Kosel M., Fisch H. U. and Pearlson G. D. (2006) Decreased frontal white-matter volume in chronic substance abuse. Drug Alcohol Depend. 77, 2330.
  • Slee E. A., Harte M. T., Kluck R. M. et al. (1999) Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2,-3,-6,-7,-8, and -10 in a caspase-9-dependent manner. J. Cell Biol. 144, 281292.
  • Stoka V., Turk B., Schendel S. L. et al. (2001) Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J. Biol. Chem. 276, 31493157.
  • Stoka V., Turk V. and Turk B. (2007) Lysosomal cysteine cathepsins; signaling pathways in apoptosis. Biol. Chem. 388, 555560.
  • Turk B., Stoka V., Rozman-Pungercar J., Cirman T., Droga-Mazovec G., Oresic K. and Turk V. (2002) Apoptotic pathways; involvement of lysosomal proteases. Biol. Chem. 382, 10351044.
  • Tzilos G. K., Cintron C. B., Wood J. B., Simpson N. S., Young A. D., Pope H. G. and Yurgelun-Todd D. A. (2005) Lack of hippocampal volume change in long-term heavy cannabis users. Am. J. Addict. 14, 6472.
  • Vancompernolle K., Van Herreweghe F., Pynaert G., Van de Craen M., De Vos K., Totty N., Sterling A., Fiers W., Vandenabeele P. and Grooten J. (1998) Atractyloside-induced release of cathepsin B, a protease with caspase-processing activity. FEBS Lett. 438, 150158.
  • Velasco G., Galve-Roperh I., Sánchez C., Blázquez C. and Guzmán M. (2004) Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacology 47, 315323.
  • Werneburg N. W., Guicciardi M. E., Bronk S. F. and Gores G. J. (2002) Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am. J. Physiol. 283, G947G956.
  • Yuan X.-M., Li W., Dalen H., Lotem J., Kama R., Sachs L. and Brunk U. T. (2002) Lysosomal destabilization in p53-induced apoptosis. Proc. Natl. Acad. Sci. USA 99, 62866291.
  • Zang Y., Beard R. L., Chandraratna R. A. and Kang J. X. (2001) Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukaemia HL-60 cells. Cell Death Differ. 8, 477485.
  • Zhao M., Eaton J. W. and Brunk U. T. (2001) Bcl-2 phosphorylation is required for inhibition of oxidative stress-induced lysosomal leak and ensuing apotosis. FEBS Lett. 14, 405412.
  • Zuzarte-Luis V., Montero J. A., Torre-Perez N., Garcia-Porrero J. A. and Hurle J. (2007) Cathepsin D gene expression outlines the areas of physiological cell death during embryonic development. Dev. Dyn. 236, 330335.